Myasthenia Gravis

Latest News

Richard J. Nowak, MD, MS | Image Credit: Yale School of Medicine
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS

June 24th 2025

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.

Myasthenia gravis diagnosis | Image Credit: Maggie L. Shaw/sora.chatgpt.com
RemeGen’s Telitacicept Gains China Approval for Myasthenia Gravis

June 19th 2025

Myasthenia Gravis | Image Credit: Bediha Duru Öksüz-stock.adobe.com
Zilucoplan Shows Rapid, Durable, Steroid-Sparing Benefits in gMG

June 12th 2025

osteoporosis | Image Credit: reineg-stock.adob.ecom
Combining Bone Health, Function Scores Refines MG Fracture Prediction

May 30th 2025

Light sensitivity is a potential symptom of myasthenia gravis that has historically been under-researched, according to study authors. | Image credit: lexiconimages - stock.adobe.com
Light Sensitivity Linked With Lower Quality of Life in Myasthenia Gravis

May 23rd 2025

More News

James Howard, MD
June 2nd 2023

Unmet Needs in Myasthenia Gravis Are Numerous, Says Dr James Howard

Allison Inserro
Unmet needs include both improved myasthenia gravis treatments as well as a way to monitor progression of the disease, said James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.
James Howard, MD
May 26th 2023

Dr James Howard on the Complications of Standard Myasthenia Gravis Therapies

Allison Inserro
Current myasthenia gravis therapies can exacerbate comorbidities or create other complications, said James F. Howard Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill.
Stressed mature business woman looking worried, tired and overwhelmed while working with laptop on a desk in the office at home: © nenetus - stock.adobe.com
May 23rd 2023

MG Has Significant Impact on Patients’ Work, Survey Shows

Jared Kaltwasser
The majority of respondents living with generalized myasthenia gravis (MG) were not working, the results showed.
James Howard, MD
May 19th 2023

Step Therapy Requirements Are Worsening, Says Dr James Howard

Allison Inserro
Myasthenia gravis expert James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the burdens that step therapy places on patients with rare diseases and their providers.
Laboratory test tubes with blood for myasthenia gravis test, diagnosis of myasthenia gravis disease, focus view: © MdBabul - stock.adobe.com
May 17th 2023

Symptom Flares Common in MuSK-Positive MG, Case Series Shows

Jared Kaltwasser
A new small case series finds higher rates of symptom flares in individuals who have muscle-specific tyrosine kinase (MuSK)–positive myasthenia gravis (MG) than previous research.
Triballs Incentive Spirometer Threeflow Respiratory Exerciser for help perform normal deep breathing exercises: © S@photo - stock.adobe.com
May 12th 2023

Preoperative Respiratory Training, Exercise Benefit Patients With MG Undergoing Thymectomy

Jared Kaltwasser
The training did not, however, affect postoperative limb skeletal muscle weakness or exercise capacity.
MYASTHENIA GRAVIS inscription on the black board MYASTHENIA GRAVIS inscription on the black board: By Yurii Kibalnik Yurii Kibalnik - stock.adobe.com
May 9th 2023

Vaccinated Patients With MG Fare Better With COVID-19, Study Finds

Jared Kaltwasser
The findings support policies urging vaccination of individuals who have myasthenia gravis (MG).
Healthy Human Lungs 2d illustration: © jijomathai - stock.adobe.com
May 2nd 2023

Single-Count Breath Test Can Help Assess Respiratory Function in MG

Jared Kaltwasser
A patient’s inability to count while holding their breath can be an indication of respiratory distress in myasthenia gravis.
image of nerves
April 29th 2023

Phase 3 Trials of Rozanolixizumab, Zilucoplan, Show Positive Results in Myasthenia Gravis

AJMC Staff
Results from 2 late-stage trials evaluating generalized myasthenia gravis therapies indicated both drugs, rozanolixizumab and zilucoplan, have potential as targeted treatment options.
image of a hospital
April 25th 2023

MG Heightens Severe COVID-19 Risk, but Vaccination Helps Reduce Risk

Jared Kaltwasser
People with myasthenia gravis (MG) had a higher risk of hospitalization for COVID-19 compared to the general population and a control group of people with rheumatoid arthritis (RA).
businessman in the middle of a maze: © SFIO CRACHO - stock.adobe.com
April 17th 2023

Refractory MG Presents Difficult Challenge for Patients, Clinicians

Jared Kaltwasser
A new case series highlights characteristics and challenges of this subgroup of patients with myasthenia gravis (MG).
James Howard, MD
April 13th 2023

Patient Needs, Antibody Subtype Should Guide Myasthenia Gravis Therapy, Says Dr James Howard

Allison Inserro
James F. Howard, Jr, MD, professor of neurology at the University of North Carolina at Chapel Hill, explains the antibody subtypes associated with this rare neuromuscular disease.
Book about Myasthenia gravis and medication, injection, syringe and pills: © mdaros - stock.adobe.com
April 11th 2023

Case of Postoperative Heart Attack Demonstrates How MG Can Complicate Cardiac Procedures

Jared Kaltwasser
A patient with myasthenia gravis (MG) quickly deteriorated after he woke up from an endovascular procedure.
Image of the words "Myasthenia gravis": © Николай Зотов - stock.adobe.com
April 3rd 2023

New Insights Into Muscle-Specific Kinase Could Impact Myasthenia Gravis, Other Diseases

Jared Kaltwasser
The new research could help identify ways to preserve neuromuscular junctions.
silhouette of little girl holding parent hand at sunse:t © nadezhda1906 - stock.adobe.com
March 31st 2023

Age of Onset an Important Clinical Factor in Triple-Negative MG

Jared Kaltwasser
Female patients were most likely to experience onset of triple-negative myasthenia gravis (MG) between ages 0 to 9 years.
Questionnaire about health problem: © Richelle - stock.adobe.com
March 28th 2023

Nomogram Developed to Predict Risk of Myasthenic Crisis Following Thymectomy

Jared Kaltwasser
The tool can help clinicians stratify patients into high-risk and low-risk categories.
Image of the words "myasthenia gravis" syahrir - stock.adobe.com
March 20th 2023

Case Report Shows Ocular MG, Autoimmune Encephalitis Can Coexist

Jared Kaltwasser
The patient received a diagnosis of myasthenia gravis (MG), then underwent a medical odyssey as physicians attempted to pin down the cause of his neurological symptoms.
The words "myasthenia gravis": Andrii - stock.adobe.com
March 17th 2023

AChR Antibody Titers May Help Predict Conversion to Generalized Myasthenia Gravis

Jared Kaltwasser
The new report suggests patients with acetylcholine receptor (AChR) antibody titers above 8.11 nmol/L were at higher risk of conversion.
general picture of antibodies
March 13th 2023

Study: MuSK-Specific Antibodies Do Not Explain Variation in Serum IgG4 Levels in People With MuSK MG

Jared Kaltwasser
People with muscle-specific kinase myasthenia gravis appear to have more active antibody responses in general, the study found.
a map of europe
March 11th 2023

German Study Finds a Third of Patients With Myasthenia Gravis Untreated After Diagnosis

Allison Inserro
The authors said it is the first study of epidemiology and real-world treatment in Germany.
image of a nerve cell
March 10th 2023

Survey of Providers Indicates Need for Improved Myasthenia Gravis Management

AJMC Staff
Myasthenia gravis affects about 60,000 individuals in the United States.
Image of a medical home
March 1st 2023

Case Report and Review Examines MG and COVID-19

Jared Kaltwasser
Just 26 cases have been reported in which myasthenia gravis (MG) symptoms appeared following vaccination.
Image of a nerve firing
February 27th 2023

RNS Not a Meaningful Prognostic Tool in Myasthenia Gravis

Jared Kaltwasser
While repetitive nerve stimulation (RNS) remains a mainstay of myasthenia gravis diagnosis, investigators said it does not appear to yield prognostic insights.
Image of targets
February 24th 2023

Inflammation Could Prove Meaningful Target in Myasthenia Gravis

Jared Kaltwasser
The article suggests the inflammatory components of myasthenia gravis have been underexplored in the effort to develop new therapies.
Image of a nerve cell
February 20th 2023

Live Cell-Based Assays May Find Antibodies in Some Seronegative MG Cases

Jared Kaltwasser
A different type of test may improve diagnosis for some patients with myasthenia gravis (MG).
Image representing a medical report
February 10th 2023

Case Shows Difficulty of Diagnosing Myasthenia Gravis Following COVID-19

Jared Kaltwasser
The patient, an 83-year-old man, experienced onset of myasthenia gravis after a severe SARS-CoV-2 infection.
Patient and doctor holding hands
February 6th 2023

Myasthenia Gravis Likely Leads to Significant Impact on QOL

Jared Kaltwasser
Even patients with the mildest symptoms of myasthenia gravis said they experienced negative quality-of-life (QOL) effects from the disease.
Image of molecular profiling
January 30th 2023

Lower CTLA4 Levels May Indicate Risk of MG in Patients With Thymoma

Jared Kaltwasser
The findings from among patients with myasthenia gravis (MG) could point the way to a potential new drug target, the authors said.
Site Logo
January 28th 2023

Ocular MG Should Be Considered in Patients With Ptosis, Diplopia, Says Study

Jaime Rosenberg
With most previous studies on ocular myasthenia gravis stemming from investigations the neurology field, the present investigators came to their conclusion via neuro-ophthalmic analysis.
picture of an intensive care unit
January 27th 2023

Clarifying the Factors in Myasthenia Gravis That Create Higher HCRU

Allison Inserro
A real-world study of health care resource utilization (HCRU) in patients with myasthenia gravis on second-line therapy identified the factors that led to increased financial burdens.
<123456>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo